InvestorsHub Logo
Followers 14
Posts 603
Boards Moderated 0
Alias Born 12/27/2017

Re: None

Sunday, 03/08/2020 1:14:36 PM

Sunday, March 08, 2020 1:14:36 PM

Post# of 403656
Wondering if we're going to actually get any update on whether the product shipped or not?

IF the clock started running with the RBL on the 27 Feb, then this week would we have an update, based on the language used from the PR they provided?

Did Leo / CoreRX / etc have raw product on-hand to actually ship?
We never learned.

Was material actually shipped?
We never learned this either.

I'm with others who feel like more specific info would be beneficial in this situation.

The now-standard 'IPIX hopes/expects-to/plans/etc' doesn't mean anything with real timelines, when actual human lives are on the line...



February 27, 2020
Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19
Brilacidin
WAKEFIELD, MA – February 27, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company signed a Material Transfer Agreement (MTA) with one of the country’s 12 Regional Biocontainment Labs (RBLs) to research its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment. As disclosed last week, the Company has been receiving inquiries about the potential to use a defensin mimetic to meet an urgent global need to treat COVID-19, the new coronavirus outbreak that began in Wuhan, China, in December and has since spread to 48 countries today without any effective approved therapies.

Now the MTA has been signed, the first shipments of Brilacidin will be made to the RBL in the coming days.

Under terms of the agreement, scientific research partners at the RBL plan to evaluate Brilacidin’s potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the virus responsible for COVID-19. Mechanism of action studies of Brilacidin, along with assessing possible synergistic effects with other antivirals, are also planned. It is anticipated these tests might be completed within several weeks of the RBL’s receipt of Brilacidin.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News